A Single arm, open label, signal seeking, Phase II a trial of the activity of seviteronel in patients with androgen receptor (AR) positive solid tumours.

ACTRN 12618001074280

Brief Summary

This study’s purpose is to facilitate and expedite the clinical testing of SEVI-D in a population with advancedat a late stage, far along cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs that are androgen receptor (AR) positive.

Intervention/Treatment

• Drug: SEVI-D

Inclusion Criteria

1. Received and failed all standard anticancer therapy or have documented unsuitability for any further standard therapy (if standard therapy exists).
2. Clinical or radiological progression on or following last anticancer therapy.
3. Patients with AR-positive solid tumours as confirmed by immunohistochemistry.
4. Adequate organ system function.
5. Ability to comply with study requirements.